 aim study investigate safety efficacy combined treatment fluvastatin (F) gemfibrozil (G) hypercholesterolemic renal transplant recipients (RTR). Ten hypercholesterolemic (total cholesterol [TC] > 220 mg/dl) RTR (7 men) mean age 44 years (range 25-56 years) remained hypercholesterolemic 3 months treatment (period A) fluvastatin (40 mg/d) continued taking dose F plus G (600 mg/dl) another 3-month period (B). Serum total cholesterol, high density lipoprotein cholesterol (HDL-C), LDL cholesterol (LDL-C), triglyceride, serum creatinine (creatinine phosphokinase (CPK), serum glutamic-oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) measured treatment end periods B. Mean TC levels 360.30 +/- 62.42 mg/dl, 324.10 +/- 100.53 mg/dl, 270.80 +/- 67.77 mg/dl; mean LDL-C levels 259.33 +/- 71.43 mg/dl, 219.60 +/- 81.31 mg/dl, 189.70 +/- 65.51 mg/dl; mean HDL-C levels 37.10 +/- 11.68 mg/dl, 39.80 +/- 13.21 mg/dl, 41.00 +/- 12.94 mg/dl; mean triglyceride levels 354.60 +/- 183.29 mg/dl, 349.30 +/- 242.94 mg/dl, 207.00 +/- 85.35 mg/dl treatment end periods B, respectively. statistically significant fall serum TC (P = 0.002), LDL-C (P = 0.016), triglyceride (P = 0.029) levels end periods B. Kidney liver function change. F G combined treatment safe useful patients respond satisfactorily monotherapy F. Gemfibrozil augments effect F TC, LDL-C, triglyceride levels.